ClinicalTrials.gg
CompletedNCT04673630TRAILHEADUpdated Jan 8, 2024Results posted

Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma

A Phase 1 interventional study of Tezepelumab in Asthma, sponsored by AstraZeneca. Completed at 6 sites in 3 countries. Open to participants aged 5 Years to 11 Years. Per ClinicalTrials.gov, last updated 2024-01-08.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
5 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.

Enrollment
26th of 28
18 · median 121
Started
2021
with 1 other
Phase 1
4 of 28
none open now
Registered
13th of 28
by date
Lead sponsor
16 of 28
AstraZeneca

Among the 28 studies testing tezepelumab in Asthma, this one is the 26th largest by enrollment, is one of 2 that started in 2021, is one of 4 in phase 1, and was the 13th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tezepelumab

tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 5 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing tezepelumab in Asthma, or all of them as a file.
02

Study summary

This study will evaluate the pharmacokinetic (PK) profile of a single subcutaneous (SC) dose of tezepelumab in children aged ≥ 5 to 11 years with asthma.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Mild asthma
  • Moderate asthma
  • Severe asthma
04

Who can participate

Ages eligible
5 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written and written informed assent and any locally required authorisation obtained from the subject and legal representative prior to any study related procedure taking place.
  • Age 5 to 11 years (inclusive) at Visit 1 and Visit 2 (Day 1). Type of Subject and Disease Characteristics
  • Documented physician diagnosed asthma for at least 6 months prior to Visit 1.
  • Documented treatment with total daily dose of either low, medium, or high dose ICS for at least 6 months, as described in Step 2 to Step 4 of GINA guidelines (GINA 2020) with stable dose for at least 3 months prior to Visit 1.
  • Pre bronchodilator (BD) of ≥ 50% of predicted normal value at Visit 1
  • Body weight ≥ 16 kg at Visit 1 and Visit 2 (Day 1).

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder other than asthma which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
  • History of a deterioration in asthma or asthma exacerbation that required a burst of systemic within 6 weeks of Visit 1, up to and including Visit 2 (Day 1).
  • History of hospitalisation (overnight admission) for asthma within 3 months of Visit 1, up to and including Visit 2 (Day 1).
  • History of a life threatening asthma exacerbation requiring intubation or mechanical ventilation.
  • History of systemic corticosteroid use for the maintenance treatment of asthma within 6 weeks of Visit 1, up to and including Visit 2 (Day 1) and discouraged until EOS.
  • History of cancer.
  • History of or anaphylactic reaction to any biologic therapy.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Tezepelumab

    Tezepelumab subcutaneous injection

    Biological: Tezepelumab

Interventions

  • BiologicalTezepelumab

    Single dose subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Maximum Observed Serum Concentration (Cmax) of Tezepelumab

    Blood samples were collected to determine the Cmax of tezepelumab. The Pharmacokinetic (PK) parameters were estimated using non-compartmental analysis method.

    Time frame: Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85

  2. Time to Achieve Maximum Observed Serum Concentration (Tmax) of Tezepelumab

    Blood samples were collected to determine the tmax of tezepelumab. The PK parameters were estimated using non-compartmental analysis method.

    Time frame: Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85

  3. Area Under the Concentration-Time Curve From Time Zero to The Last Measurable Concentration (AUC0-last) of Tezepelumab

    Blood samples were collected to determine the AUC0-last of tezepelumab and calculated by linear up/log down trapezoidal summation. The PK parameters were estimated using non-compartmental analysis method.

    Time frame: Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85

  4. Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Tezepelumab

    Blood samples were collected to determine the AUC0-inf of tezepelumab and calculated by linear up/log down trapezoidal summation and extrapolated to infinity by the addition of the last quantifiable concentration divided by the terminal rate constant. The PK parameters were estimated using non-compartmental analysis method.

    Time frame: Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85

  5. Terminal Phase Elimination Half-Life (t1/2) of Tezepelumab

    Blood samples were collected to determine the t1/2 of tezepelumab and calculated as ln(2)/λZ, where λZ is the first-order rate constant associated with the terminal (log-linear) elimination phase. The PK parameters were estimated using non-compartmental analysis method.

    Time frame: Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85

  6. Apparent Clearance (CL/F) of Tezepelumab

    Blood samples were collected to determine the CL/F of tezepelumab and estimated as dose divided by AUC0-inf. The PK parameters were estimated using non-compartmental analysis method.

    Time frame: Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85

  7. Apparent Steady-State Volume of Distribution (Vss/F) of Tezepelumab

    Blood samples were collected to determine the Vss/F of tezepelumab and estimated as CL/F\*mean residence time (MRT), where MRT=Area under the moment curve of the analyte in the sampled matrix from zero (predose) extrapolated to infinite time/(AUC0-inf). The PK parameters were estimated using non-compartmental analysis method.

    Time frame: Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85

  8. Apparent Volume of Distribution (Vz/F) of Tezepelumab

    Blood samples were collected to determine the Vz/F of tezepelumab and estimated as CL/F\*1/ λZ. The PK parameters were estimated using non-compartmental analysis method.

    Time frame: Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85

Secondary outcomes

  1. Number of Participants With Anti-Drug Antibody (ADA) Response to Tezepelumab

    Blood samples were analyzed for the presence of ADAs for tezepelumab using validated assays. ADA prevalence was defined as ADA positive at baseline and/or post baseline. ADA incidence was defined as the percentage of treatment-emergent ADA positive participants in a population. Treatment induced ADA positive was defined as ADA negative at baseline and post-baseline ADA positive. Treatment-boosted ADA positive was defined as baseline positive ADA titre that was boosted to a 4-fold or higher level following study drug administration. Treatment-emergent ADA positive was defined as either treatment-induced ADA positive or treatment-boosted ADA positive.

    Time frame: Predose and within ± 1 hour of postdose on Day 1; on Days 29 and 85

07

Results

Posted Jan 8, 2024

Participant flow

This Phase I open-label study was conducted in pediatric participants with mild, moderate, or severe asthma at 6 investigational sites in the UK, Hungary, and South Africa between 23 February 2021 and 27 September 2022.

Participant flow — Overall Study
MilestoneTezepelumab
Started18
Completed18
Not completed0

Outcome measures

PrimaryMaximum Observed Serum Concentration (Cmax) of Tezepelumab

Blood samples were collected to determine the Cmax of tezepelumab. The Pharmacokinetic (PK) parameters were estimated using non-compartmental analysis method.

Time frame:
Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85
Reported as:
Mean · microgram per milliliter (mcg/mL)
Maximum Observed Serum Concentration (Cmax) of Tezepelumab
microgram per milliliter (mcg/mL)Tezepelumab
Maximum Observed Serum Concentration (Cmax) of Tezepelumab27.1 ± 11.9
PrimaryTime to Achieve Maximum Observed Serum Concentration (Tmax) of Tezepelumab

Blood samples were collected to determine the tmax of tezepelumab. The PK parameters were estimated using non-compartmental analysis method.

Time frame:
Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85
Reported as:
Median · day
Time to Achieve Maximum Observed Serum Concentration (Tmax) of Tezepelumab
dayTezepelumab
Time to Achieve Maximum Observed Serum Concentration (Tmax) of Tezepelumab3.47 (1.92 to 9.96)
PrimaryArea Under the Concentration-Time Curve From Time Zero to The Last Measurable Concentration (AUC0-last) of Tezepelumab

Blood samples were collected to determine the AUC0-last of tezepelumab and calculated by linear up/log down trapezoidal summation. The PK parameters were estimated using non-compartmental analysis method.

Time frame:
Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85
Reported as:
Mean · day*mcg/mL
Area Under the Concentration-Time Curve From Time Zero to The Last Measurable Concentration (AUC0-last) of Tezepelumab
day*mcg/mLTezepelumab
Area Under the Concentration-Time Curve From Time Zero to The Last Measurable Concentration (AUC0-last) of Tezepelumab872 ± 285
PrimaryArea Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Tezepelumab

Blood samples were collected to determine the AUC0-inf of tezepelumab and calculated by linear up/log down trapezoidal summation and extrapolated to infinity by the addition of the last quantifiable concentration divided by the terminal rate constant. The PK parameters were estimated using non-compartmental analysis method.

Time frame:
Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85
Reported as:
Mean · day*mcg/mL
Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Tezepelumab
day*mcg/mLTezepelumab
Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Tezepelumab974 ± 320
PrimaryTerminal Phase Elimination Half-Life (t1/2) of Tezepelumab

Blood samples were collected to determine the t1/2 of tezepelumab and calculated as ln(2)/λZ, where λZ is the first-order rate constant associated with the terminal (log-linear) elimination phase. The PK parameters were estimated using non-compartmental analysis method.

Time frame:
Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85
Reported as:
Mean · day
Terminal Phase Elimination Half-Life (t1/2) of Tezepelumab
dayTezepelumab
Terminal Phase Elimination Half-Life (t1/2) of Tezepelumab25.7 ± 5.94
PrimaryApparent Clearance (CL/F) of Tezepelumab

Blood samples were collected to determine the CL/F of tezepelumab and estimated as dose divided by AUC0-inf. The PK parameters were estimated using non-compartmental analysis method.

Time frame:
Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85
Reported as:
Mean · liter per day
Apparent Clearance (CL/F) of Tezepelumab
liter per dayTezepelumab
Apparent Clearance (CL/F) of Tezepelumab0.0802 ± 0.0295
PrimaryApparent Steady-State Volume of Distribution (Vss/F) of Tezepelumab

Blood samples were collected to determine the Vss/F of tezepelumab and estimated as CL/F\*mean residence time (MRT), where MRT=Area under the moment curve of the analyte in the sampled matrix from zero (predose) extrapolated to infinite time/(AUC0-inf). The PK parameters were estimated using non-compartmental analysis method.

Time frame:
Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85
Reported as:
Mean · liter
Apparent Steady-State Volume of Distribution (Vss/F) of Tezepelumab
literTezepelumab
Apparent Steady-State Volume of Distribution (Vss/F) of Tezepelumab3.08 ± 1.32
PrimaryApparent Volume of Distribution (Vz/F) of Tezepelumab

Blood samples were collected to determine the Vz/F of tezepelumab and estimated as CL/F\*1/ λZ. The PK parameters were estimated using non-compartmental analysis method.

Time frame:
Predose and within ± 1 hour of postdose on Day 1; on Days 3, 7, 11, 15, 29, 57 and 85
Reported as:
Mean · liter
Apparent Volume of Distribution (Vz/F) of Tezepelumab
literTezepelumab
Apparent Volume of Distribution (Vz/F) of Tezepelumab2.98 ± 1.26
SecondaryNumber of Participants With Anti-Drug Antibody (ADA) Response to Tezepelumab

Blood samples were analyzed for the presence of ADAs for tezepelumab using validated assays. ADA prevalence was defined as ADA positive at baseline and/or post baseline. ADA incidence was defined as the percentage of treatment-emergent ADA positive participants in a population. Treatment induced ADA positive was defined as ADA negative at baseline and post-baseline ADA positive. Treatment-boosted ADA positive was defined as baseline positive ADA titre that was boosted to a 4-fold or higher level following study drug administration. Treatment-emergent ADA positive was defined as either treatment-induced ADA positive or treatment-boosted ADA positive.

Time frame:
Predose and within ± 1 hour of postdose on Day 1; on Days 29 and 85
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibody (ADA) Response to Tezepelumab
ParticipantsTezepelumab
ADA prevalence3
Only baseline ADA positive2
Baseline and at least 1 post-baseline ADA positive1
Baseline ADA positive regardless of post-baseline3
Any post-baseline ADA positive1
Treatment-induced ADA positive0
Treatment-boosted ADA positive0
Treatment-emergent ADA positive0

Adverse events

Collected over From the first dose administration (Day 1) up to study completion (End of Study/Day 85 visit) or withdrawal date. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tezepelumab0/18 (0%)0/18 (0%)7/18 (38.9%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventTezepelumab
COVID-19Infections and infestations2/18
NasopharyngitisInfections and infestations2/18
HeadacheNervous system disorders2/18
Viral upper respiratory tract infectionInfections and infestations1/18
AsthmaRespiratory, thoracic and mediastinal disorders1/18
CoughRespiratory, thoracic and mediastinal disorders1/18
VomitingGastrointestinal disorders1/18
PyrexiaGeneral disorders1/18
Seasonal allergyImmune system disorders1/18
ContusionInjury, poisoning and procedural complications1/18

Baseline characteristics

The Safety analysis set included all participants who received at least 1 dose of tezepelumab.

Age, Continuous
Age, Continuous(years)Tezepelumab
Mean7.9 ± 1.78
Sex: Female, Male
Sex: Female, Male(Participants)Tezepelumab
Female7
Male11
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tezepelumab
Asian2
Black or African American1
White6
Other9
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tezepelumab
Not Hispanic or Latino18
08

Study locations

6 sites
  • Research Site
    Budapest, 1094, Hungary
  • Research Site
    Cape Town, 7700, South Africa
  • Research Site
    Bristol, BS2 8BJ, United Kingdom
  • Research Site
    Glasgow, G51 4TF, United Kingdom
  • Research Site
    London, E1 1BB, United Kingdom
  • Research Site
    London, SE5 9RS, United Kingdom
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Sep 2022, 19 months.

Results were first posted in Jan 2024, 1 year 3 months after primary completion.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 19 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2020
First posted
Dec 17, 2020
StartActual
Feb 23, 2021
Primary completionActual
Sep 27, 2022
CompletionActual
Sep 27, 2022
Results first posted
Jan 8, 2024
Last update
Jan 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04673630
Lead sponsor
AstraZeneca
Collaborators
Amgen
Responsible party
Sponsor
First posted
Dec 17, 2020
Start date
Feb 23, 2021
Primary completion
Sep 27, 2022
Completion
Sep 27, 2022
Results posted
Jan 8, 2024
Last update
Jan 8, 2024

Study contacts

Jonathan Grigg, MD
principal investigator · Royal London Hospital, United Kingdom

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion